Amylyx Pharmaceuticals, Inc. AMLX R2KR3KPHARMA
Company Overview
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +310.84% |
| 6 Months: | +146.21% |
| 3 Months: | +156.01% |
| 1 Month: | +40.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMLX Amylyx Pharmaceuticals, Inc. R2KR3KPHARMA | 34.10 | -24.18 | $3.80B | 0.00% | -49.46% | -74.73% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 345.00K | 71.43M | 98.22M | 102.69M | 88.64M | -1.02M | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.80M | 42.86M | 36.03M | 36.60M | 43.78M | - |
| Operating Income | -12.87M | -18.59M | -22.92M | -47.81M | -54.25M | -54.68M | -2.05M | 20.20M | 18.72M | -122.13M | -76.29M | - | - | -37.80M | -42.86M | -36.03M | -36.60M | -43.78M | -45.69M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -37.65M | -42.72M | -35.91M | -36.50M | -43.68M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -35.91M | -41.44M | -34.39M | -32.95M | -41.28M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -635.00K | 0 | 0 | 0 | 46.00K | - | - |
| Net Income | -14.52M | -21.92M | -23.14M | -47.85M | -54.07M | -53.76M | 1.57M | 22.07M | 20.89M | -118.79M | -72.70M | - | - | -35.91M | -41.44M | -34.39M | -33.00M | -41.28M | -43.42M |
| Diluted EPS | - | -3.41 | -3.42 | -0.93 | -0.93 | -0.92 | 0.02 | 0.31 | 0.30 | -1.75 | -1.07 | - | - | -0.42 | -0.46 | -0.37 | -0.30 | -0.37 | -0.39 |
| R&D Expense | 6.86M | 10.93M | 12.85M | 21.46M | 24.26M | 24.91M | 24.19M | 29.04M | 30.04M | 36.61M | 23.35M | 21.24M | - | 22.12M | 27.22M | 19.86M | - | 27.61M | 23.77M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 22.23M | 380.79M | 87.37M | 0 |
| Cost of Revenue | - | 2.99M | 25.44M | 124.63M | 0 |
| Gross Profit | - | 19.24M | 355.35M | -37.26M | 0 |
| Operating Expenses | - | 220.58M | 316.54M | 218.41M | 153.29M |
| Operating Income | - | -201.34M | 38.80M | -255.68M | -153.29M |
| EBITDA | - | -200.85M | 39.89M | -254.77M | -152.77M |
| Interest Expense | 0 | - | - | - | - |
| Pretax Income | - | -197.60M | 54.30M | -302.14M | -144.69M |
| Tax Provision | - | 774.00K | 5.03M | -393.00K | 46.00K |
| Net Income | - | -198.38M | 49.27M | -301.74M | -144.74M |
| Diluted EPS | - | -3.39 | 0.70 | -4.43 | -1.53 |
| R&D Expense | 44.04M | 93.45M | 128.19M | 104.08M | 90.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 391.45M | 517.45M | 193.63M | 332.64M |
| Current Assets | - | - | 382.13M | 464.67M | 189.43M | 323.67M |
| Cash & Equivalents | - | - | 62.53M | 170.20M | 77.39M | 226.65M |
| Inventory | - | 0 | 9.77M | 38.32M | 0 | - |
| Receivables | - | - | 15.31M | 40.05M | 447.00K | 88.00K |
| Total Liabilities | - | - | 50.85M | 84.02M | 28.87M | 27.39M |
| Current Liabilities | - | - | 46.61M | 82.04M | 28.41M | 22.69M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 6.28M | 4.24M | 1.98M | 5.96M |
| Total Equity | -66.72M | - | 340.61M | 433.43M | 164.76M | 305.26M |
| Shares Outstanding | - | - | 66.51M | 67.71M | 68.63M | 109.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -179.87M | 11.92M | -167.65M | -123.34M |
| Investing Cash Flow | - | -238.99M | 92.05M | 75.65M | 14.04M |
| Financing Cash Flow | - | 431.79M | 3.54M | 348.00K | 257.03M |
| Capital Expenditure | - | -2.53M | -1.24M | -157.00K | -138.00K |
| Free Cash Flow | - | -182.40M | 10.68M | -167.80M | -123.48M |
| Net Change in Cash | - | 12.93M | 107.52M | -91.64M | 147.72M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 86.5% | 93.3% | -42.6% | - |
| Operating Margin % | - | -905.7% | 10.2% | -292.6% | - |
| Net Margin % | - | -892.4% | 12.9% | -345.4% | - |
| ROE % | - | -58.2% | 11.4% | -183.1% | -47.4% |
| ROCE % | - | -58.4% | 8.9% | -154.7% | -49.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 15.01% | 16.73M | $581.13M |
| 2 | Blackrock Inc. | 7.92% | 8.83M | $306.65M |
| 3 | Perceptive Advisors Llc | 7.48% | 8.33M | $289.55M |
| 4 | TCG Crossover Management, LLC | 5.60% | 6.24M | $216.91M |
| 5 | Commodore Capital Lp | 5.07% | 5.65M | $196.28M |
| 6 | Jupiter Topco LLC | 4.70% | 5.24M | $181.90M |
| 7 | Saturn V Capital Management LP | 4.15% | 4.62M | $160.64M |
| 8 | Vanguard Capital Management LLC | 3.79% | 4.22M | $146.75M |
| 9 | Morgan Stanley | 2.81% | 3.13M | $108.76M |
| 10 | Driehaus Capital Management, LLC | 2.73% | 3.04M | $105.50M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMLX
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx looks promising, but a pullback would improve the opportunity.
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
The biotech delivered excellent news from the laboratory.
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday down 0.9% at $21.43, then traded 15.7% higher at $24.80 after hours after the comp…
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?
Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence.
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
CAMBRIDGE, Mass., August 20, 2026--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering …
Amylyx Pharmaceuticals (AMLX) Posts Phase 3 Avexitide Win And Follows With Equity Raise
Amylyx Pharmaceuticals (NasdaqGS: AMLX) reported overwhelmingly positive topline Phase 3 results for avexitide in post-bariatric hypoglycemia, with the trial meeting its primary and all secondary endpoints. The data support a planned NDA fi…
AMLX — Frequently Asked Questions
What is the current share price of Amylyx Pharmaceuticals, Inc. (AMLX)?
As of 2026-09-07 16:24 PDT, Amylyx Pharmaceuticals, Inc. (AMLX) trades at $34.10 on NasdaqGS. Its 52-week range is $7.82 to $39.66.
What is the market capitalisation of AMLX?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalisation of $3.80B on NasdaqGS.
What is the P/E ratio of AMLX?
AMLX trades at a trailing price-to-earnings (P/E) ratio of -24.18. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 10.61.
What is the return on equity (ROE) of AMLX?
AMLX has a return on equity (ROE) of -74.73%. Its return on capital employed (ROCE) is -49.46%.
Is AMLX a good stock to buy?
This page provides a data-driven analysis of Amylyx Pharmaceuticals, Inc. (AMLX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.